MYCN and neuroblastoma: Profiling of super enhancers and their target genes has led to molecular identification of super-enhancer-driven neuroblastoma subtypes that match known clinical groups, including MYCN-amplified, non-MYCN-amplified high-risk, and low-risk neuroblastoma tumors [164].